Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: A proposal for standardization of patient characteristic reporting and stratification

Annals of Oncology

Volumn 18, Issue 10, 2007, Pages 1666-1672

  Sorbye, H ^a   Kohne C H ^b   Sargent, D J ^c   Glimelius, B ^d,e  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b Klinik fur Innere Medizin   (Germany)

^c MAYO CLINIC CANCER CENTER   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Colorectal neoplasm; Metastatic disease; Patient characteristics; Prognosis; Stratification

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; LACTATE DEHYDROGENASE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; STANDARDIZATION;

AGED; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; PROGNOSIS;

EID: 34848887988     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm267     Document Type: Article

References (36)

1. Bajorin D. The phase III candidate: Can we improve in the science of selection? J Clin Oncol 2004; 22: 211-213.
2. Sloan JA, Loprinzi CL, Laurine JA et al. A simple stratification factor prognostic for survival in advanced cancer: The Good/Bad/Uncertain index. J Clin Oncol 2001; 19: 3539-3546.
3. Köhne CH, Cunningham D, Di Costanzo F et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317.
4. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
5. Mitry E, Douillard JY, van Cutsem E et al. Predictive factors of survival in patients with advanced colorectal cancer: An individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004; 15: 1013-1017.
6. Giachetti S, Perponit B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
7. Freyer G, Rougier P, Bugat R et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. Br J Cancer 2000; 83: 431-437.
8. Bensmaine MA, Marty M, de Gramont A et al. Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU resistant advanced colorectal cancer patients. Br J Cancer 2001; 85: 509-517.
9. Cunningham D, Pyrhonen S, James RD et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
10. Rougier P, Van Cutsem E, Bajetta C et al. Randomized trial of irinotecan versus fluorouracil by continuos infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
11. Pfeiffer P, Sorbye H, Ehrsson H et al. Short-time infusion of oxaliplatin in combination with capecitabine (XELOX) as second line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. Ann Oncol 2006; 17: 252-258.
12. Kabbinavar F, Zurlo A, Irl C, Hurwitz H. Bevacizumab improves outcomes of patients with mCRC treated with IFL with or witiout bevacizumab independent of baseline risk. Proc Am Soc Clin Oncol 2006; 24: 155s abs. 3539.
13. Sorbye H, Glimelius B. Berglund Å et al. Multicentre phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004; 22: 31-38.
14. Zia MI, Siu LL, Pond GR, Chen EX. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol 2005; 23: 6982-6991.
15. Siu LL, Tannock IF. Problems in interpreting clinical trials. In Crowley J (ed): Handbook of Statistics in Clinical Oncology. New York, NY: Marcel Dekker Inc 2001; 473-490.
16. Lamont EB, Hayreh D, Pickett KE et al. Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst 2003; 95: 1370-1375.
17. George SL. Selection bias, phase II trials and the FDA accelerated approval process. J Natl Cancer Inst 2003; 95: 1351-1352.
18. Brawley OW. The study of accrual to clinical trials: Can we learn from studying who enters our studies? J Clin Oncol 2004; 22: 2039-2040.
19. George SL. Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol 1996; 14: 1364-1370.
20. Begg C, Cho M, Eastwood S et al. Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA 1996; 276: 637-639.
21. Wils J, Sahmoud T, Sobrero A et al. Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. Tumouri 1998; 84: 335-347.
22. Martin RCG, Augenstein VA, Scoggins CR et al. Quality of survival reporting in chemotherapy and surgical trials in patients with metastatic colorectal carcinoma. Cancer 2006; 106: 1389-1394.
23. Wright JR, Bouma S, Dayes I et al. The Importance of reporting patient recruitment details in phase III trials. J Clin Oncol 2006; 24: 843-845.
24. Toumigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
25. Fuchs CS, Moore MR. Harker G et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer J Clin Oncol 2003; 21: 807-814.
26. Wils J, Blijham GH, Wagener T et al. High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer in a randomised phase II-III trial of the EORTC Gastrointestinal Group. Eur J Cancer 2003; 39: 346-352.
27. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1. A randomized study of FOLFOX4 or FOLFOX/with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - A GERCOR study. J Clin Oncol 2006; 24: 394-400.
28. Kemeny NE, Niedzwieki D, Hollis DR et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: A randomized trial of efficacy, quality of life, and molecular markers. J Clin Oncol 2006; 24: 1395-1403.
29. Tampellini M, Saini A, Alabiso I et al. The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients. Br J Cancer 2006; 95: 13-20.
30. Major P, Trarbach T, Lenz HJ et al. Meta-analysis of two randomized, doubleblind placebo-controlled, phase III studies in patients with metastatic oolorectal cancer receiving FOLFOX4 and PTK/ZK to determine clinical benefit using progression-free survival in high LDH patients. Proc Am Soc Clin Oncol 2006; 24: 153s abs 3529.
31. Koukourakis MI, Giatromanolaki A, Simopoulos C et al. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis 2005; 22: 25-30.
32. Kozloff M, Hainsworth J, Badarinath S et al. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRITE). Proc Am Soc Clin Oncol 2006; 24: 155s abs 3537.
33. Berry SR, Cunningham D, Michael M et al. Preliminary safety of bevacizumab with first-line FOLFOX, XELOX. FOLFIRI and capecitabine for mCRC-first BEAT trial. Proc Am Soc Clin Oncol 2006; 24: 154s abs 3534.
34. Sorbye H, Berglund Å, Tveit KM et al. Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer. Acta Oncol 2007; in press.
35. Keman WN, Viscoli CM, Makuch RW et al. Stratified randomization for clinical trials. J Clin Epidemiol 1999; 52: 19-26.
36. Nam JM. Sample size determination in stratified trials to establish the equivalence of two treatments. Stat Med 1995; 14: 2037-2049.